What is FEops?
Founded in 2009, FEops has established itself as a leader in the digital health landscape, specifically targeting the complexities of heart disease. By integrating advanced computational modeling with clinical workflows, the company provides physicians with unique, actionable insights that improve the efficacy of cardiovascular procedures. As a scale-up, FEops occupies a vital niche in the intersection of life sciences and software engineering, effectively bridging the gap between diagnostic imaging and surgical planning. Their market position is reinforced by a commitment to evidence-based innovation, allowing them to navigate the rigorous regulatory environments of the global healthcare industry while maintaining a focus on patient-centric outcomes.
How much funding has FEops raised?
FEops has raised a total of $12M across 3 funding rounds:
Series A
$1.5M
Series B
$7.2M
Debt
$3.3M
Series A (2015): $1.5M with participation from Capricorn Venture Partners and PMVenture
Series B (2017): $7.2M led by Capricorn Venture Partners, Valiance, and PMV
Debt (2022): $3.3M supported by The European Innovation Council
Key Investors in FEops
Capricorn Venture Partners
An independent manager specializing in venture and growth capital, focusing on innovative European companies within the digital, health, and clean technology sectors.
Valiance
A global investment firm that collaborates with impactful technology businesses, emphasizing social impact alongside financial returns to improve quality of life.
PMV
A strategic financial partner supporting the growth of start-ups and mature SMEs through tailored financing, with deep expertise in life sciences and sustainable infrastructure.
What's next for FEops?
Looking ahead, the recent strategic financing will likely be deployed to accelerate the commercial expansion of FEops' digital platforms and deepen their research and development capabilities. As the company transitions from a scale-up phase toward broader enterprise-level adoption, the focus will shift toward integrating their predictive tools into standard clinical practice across international markets. By leveraging this capital, FEops is well-positioned to solidify its competitive advantage, potentially expanding its product suite to address a wider array of cardiovascular conditions and further cementing its role as an essential partner for healthcare providers seeking to enhance procedural precision and long-term patient health.
See full FEops company page
